A randomized controlled trial of the impact of dopamine on outcome of asphyxiated neonates
Abstract
Abstract: Background: Vasoactive drugs such as low dosage dopamine are often used in the intensive care of asphyxiated term neonates but there is insufficient evidence to support the practice.
Aims: To evaluate the impact of low dose dopamine on the clinical course and outcome of newborns with severe perinatal asphyxia and to determine factors that predict survival.
Methods: This was a randomized controlled trial. Term asphyxiated newborns were alternately recruited into ‘dopamine’ and ‘no- dopamine’ sub groups. Asphyxia was defined as Apgar score ≤3 at one minute or ≤5 at five minutes, and/or clinical evidence of hypoxic ischemic encephalopathy (HIE). The intervention comprised dopamine infusion at 3.0mcg/kg/minute. Primary outcome was death or survival till discharge while secondary measures were apnoea, oliguria, seizures and other clinical morbidities. The Student t-test was used to compare outcomes between the subgroups.
Results: A total of fifty five asphyxiated infants took part in the study: 27 in the intervention group while 28 were in the control group. The subgroups were similar in mean gestational age, Apgar scores, age at admission and modes of delivery (p>0.05). HIE occurred in over a half of the subjects. The frequency of apnoea, oxygen requirement, duration of anticonvulsant treatment and urine outputs were similar between the subgroups(p > 0.05).The mean durations of admission (days) were 5.13±3.0 and 5.3±3.0 for the intervention and non-intervention subgroups respectively (t=0.183, p=0.856). Likewise, survival rates were similar (x2 = 1.261, p = 0.948). Selected perinatal events did not influence outcome (p>0.05).
Conclusion: Low-dosedopamine has no impact on the short term outcome of asphyxiated infants.
Keywords: hypoxic ischemic encephalopathy, clinical course, outcome, dopamine
Downloads
Published
Issue
Section
License
This is an open-access journal, and articles are distributed under the terms of the Creative Commons Attribution 4.0 License, which allows others to remix, transform, and build upon the work even, commercially, as long as appropriate credit is given to the author, and the new creations are licensed under identical terms